Thiogenesis Therapeutics Corp
TTI.V
Toronto Stock Exchange Ventures0.49
CAD
- -
- -
ISIN
CA88410L1022
CUSIP
88410L102
Return %
Stock
S&P500
1Y
-30.00
15.01
3Y
-37.97
82.56
5Y
-2.00
79.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Patrice Rioux
- Sector
- Financial Services
- Industry
- Financial - Conglomerates
- Address
- 4 King Street West Toronto ON Canada M5H 1B6
- IPO Date
- Apr 13, 2022
- Website
- thiogenesis.com
- Similar Companies
- Business
- Thiogenesis Therapeutics Corp. is a clinical-stage biopharmaceutical company that develops sulfur-containing, thiol-based prodrugs for rare pediatric, metabolic and mitochondrial diseases characterized by oxidative stress and mitochondrial dysfunction. Its principal product candidate is TTI-0102, a proprietary, once-daily controlled-release cysteamine prodrug designed to generate intracellular cysteine, support glutathione production and improve tolerability, bioavailability and dosing convenience relative to established cysteamine therapies. TTI-0102 is in late-stage development for nephropathic cystinosis and is being evaluated or advanced for primary mitochondrial diseases, including mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) and Leigh syndrome spectrum disorders; the company also identifies potential future applications in pediatric metabolic dysfunction-associated steatotic liver disease/steatohepatitis, as well as other inherited and acquired mitochondrial and metabolic disorders. The company’s development activities include clinical trials, investigator-initiated studies and regulatory programs directed toward patients with significant unmet medical needs, principally in the United States and Europe. Thiogenesis Therapeutics was founded in 2018 and maintains operations in San Diego, California, with corporate ties to Canada and a TSX Venture Exchange listing under the symbol TTI. Recent developments include the completion in June 2026 of an oversubscribed non-brokered private placement that generated gross proceeds of C$9.07 million; the initiation of an investigator-initiated cystinosis study with Dr. Larry Greenbaum announced in February 2026; presentation of interim Phase 2 MELAS data at Mitocon 2026; the FDA’s July 2026 grant of Rare Pediatric Disease designation to TTI-0102 for Leigh syndrome; planned initiation of a Phase 2 trial in Leigh syndrome spectrum disorders with a leading U.S. children’s hospital during 2026; the appointment of Gilad Aharon, Ph.D., to its board in June 2026; and the September 2026 engagement of Brisco Capital Partners Corp. for investor-relations services.